Oak Ridge Investments LLC Makes New Investment in Glaukos Co. (NYSE:GKOS)

Oak Ridge Investments LLC acquired a new position in shares of Glaukos Co. (NYSE:GKOS - Free Report) during the fourth quarter, according to the company in its most recent disclosure with the SEC. The firm acquired 11,150 shares of the medical instruments supplier's stock, valued at approximately $1,672,000.

Several other institutional investors have also recently made changes to their positions in GKOS. Envestnet Asset Management Inc. grew its position in shares of Glaukos by 3.6% during the 2nd quarter. Envestnet Asset Management Inc. now owns 67,936 shares of the medical instruments supplier's stock valued at $8,040,000 after acquiring an additional 2,341 shares during the period. Wealth Alliance purchased a new position in Glaukos during the second quarter worth approximately $246,000. Intech Investment Management LLC acquired a new stake in Glaukos in the second quarter valued at approximately $1,346,000. Brighton Jones LLC purchased a new stake in shares of Glaukos in the second quarter valued at approximately $208,000. Finally, Sei Investments Co. raised its stake in shares of Glaukos by 51.6% during the 2nd quarter. Sei Investments Co. now owns 108,546 shares of the medical instruments supplier's stock worth $12,847,000 after buying an additional 36,933 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Insider Activity

In other Glaukos news, COO Joseph E. Gilliam sold 2,275 shares of the stock in a transaction dated Wednesday, October 30th. The shares were sold at an average price of $138.97, for a total transaction of $316,156.75. Following the completion of the transaction, the chief operating officer now owns 102,169 shares of the company's stock, valued at $14,198,425.93. This trade represents a 2.18 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, Director Gilbert H. Kliman sold 2,000 shares of Glaukos stock in a transaction dated Wednesday, December 11th. The shares were sold at an average price of $144.01, for a total transaction of $288,020.00. Following the sale, the director now owns 32,336 shares of the company's stock, valued at approximately $4,656,707.36. This represents a 5.82 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 17,603 shares of company stock valued at $2,605,678. 6.40% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

A number of research firms recently issued reports on GKOS. Morgan Stanley cut shares of Glaukos from an "equal weight" rating to an "underweight" rating and set a $120.00 price target on the stock. in a research note on Monday, December 2nd. Stifel Nicolaus lifted their target price on shares of Glaukos from $153.00 to $175.00 and gave the company a "buy" rating in a research report on Tuesday, December 31st. Stephens upgraded shares of Glaukos to a "strong-buy" rating in a research report on Monday, December 2nd. UBS Group assumed coverage on shares of Glaukos in a research note on Friday, December 6th. They issued a "buy" rating and a $182.00 price target on the stock. Finally, JPMorgan Chase & Co. boosted their price objective on Glaukos from $130.00 to $145.00 and gave the stock an "overweight" rating in a research note on Tuesday, November 5th. One equities research analyst has rated the stock with a sell rating, two have assigned a hold rating, ten have given a buy rating and one has issued a strong buy rating to the stock. According to data from MarketBeat.com, Glaukos presently has an average rating of "Moderate Buy" and a consensus target price of $147.75.

Glaukos Trading Up 0.1 %

Shares of GKOS traded up $0.09 during midday trading on Friday, reaching $156.60. The company had a trading volume of 529,055 shares, compared to its average volume of 558,098. The firm has a 50 day simple moving average of $145.94 and a 200-day simple moving average of $133.60. The company has a quick ratio of 4.71, a current ratio of 5.54 and a debt-to-equity ratio of 0.19. The stock has a market cap of $8.63 billion, a PE ratio of -51.85 and a beta of 1.04. Glaukos Co. has a 1-year low of $83.90 and a 1-year high of $161.13.

Glaukos (NYSE:GKOS - Get Free Report) last released its quarterly earnings data on Monday, November 4th. The medical instruments supplier reported ($0.28) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.48) by $0.20. Glaukos had a negative net margin of 42.43% and a negative return on equity of 18.99%. The firm had revenue of $96.70 million during the quarter, compared to analysts' expectations of $91.50 million. During the same period last year, the business earned ($0.50) earnings per share. Glaukos's revenue was up 23.9% compared to the same quarter last year. Research analysts forecast that Glaukos Co. will post -1.89 EPS for the current fiscal year.

About Glaukos

Glaukos Corporation, an ophthalmic pharmaceutical and medical technology company, focuses on the development of novel therapies for the treatment of glaucoma, corneal disorders, and retinal diseases. It offers iStent and iStent inject W micro-bypass stents that enhance aqueous humor outflow inserted in cataract surgery to treat mild-to-moderate open-angle glaucoma.